Holen Sie sich die Stockscreener-App
50.08
4.48%
-2.35
Schlusskurs vom Vortag:
$52.43
Offen:
$52
24-Stunden-Volumen:
2.31M
Relative Volume:
1.24
Marktkapitalisierung:
$4.72B
Einnahmen:
$536.20M
Nettoeinkommen (Verlust:
$-45.64M
KGV:
-93.64
EPS:
-0.5348
Netto-Cashflow:
$-28.94M
1W Leistung:
+0.97%
1M Leistung:
-16.30%
6M Leistung:
+22.68%
1J Leistung:
+77.90%
1-Tages-Spanne:
$49.78
$52.22
1-Wochen-Bereich:
$49.74
$54.83
52-Wochen-Spanne:
$22.59
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
50.08 | 4.72B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
The CEO exercises options at $8.93 and sells shares in Travere Therapeutics (TVTX). - Stock Titan
An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com India
Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing - Yahoo Finance
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing - Yahoo Finance
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing - Yahoo Finance
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Nigeria
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere CFO (NASDAQ: TVTX) sells 50K shares in pre-set trading plan - Stock Titan
Travere Therapeutics (TVTX) CEO trades 400K shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Canada
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com
Travere Therapeutics (NASDAQ: TVTX) officer plans 112,850-share sale after recent 96,198-share trade - Stock Titan
After $6M sale, Travere (NASDAQ: TVTX) insider plans another stock move - Stock Titan
Travere Therapeutics (TVTX) insider plans 172,717-share sale after option exercise - Stock Titan
Insider plans 39,576-share sale at Travere Therapeutics (NASDAQ: TVTX) in 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer may sell shares after cashing in options - Stock Titan
$2.9M planned stock sale at Travere (NASDAQ: TVTX) comes from equity awards - Stock Titan
Over 100,000 Travere (NASDAQ: TVTX) shares lined up for insider sale - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans Rule 144 sale of compensation shares - Stock Titan
TVTX Form 4 FilingsTravere Therapeutics, Inc. SEC Form 4 - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan
Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews
Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia
Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan
TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com UK
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Nigeria
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ERIC DUBE | Director |
Oct 15 '26 |
Proposed Sale |
53.27 |
243,735 |
12,983,763 |
0 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Oct 15 '26 |
Sale |
53.82 |
243,735 |
13,116,671 |
432,886 |
| ERIC DUBE | Director |
Sep 17 '26 |
Proposed Sale |
63.48 |
108,493 |
6,887,136 |
0 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
22.40 |
8,282 |
185,517 |
125,348 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Option Exercise |
23.34 |
108,493 |
2,532,227 |
541,379 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Sale |
64.61 |
108,493 |
7,009,671 |
432,886 |
| PETER HEERMA | Officer |
Sep 17 '26 |
Proposed Sale |
63.48 |
8,282 |
525,741 |
0 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Sale |
65.07 |
8,282 |
538,917 |
117,066 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Option Exercise |
23.34 |
195,841 |
4,570,929 |
628,727 |
| ERIC DUBE | Director |
Sep 16 '26 |
Proposed Sale |
62.51 |
195,841 |
12,242,021 |
0 |
1.20%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):